Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Liver Physiology01:30

Liver Physiology

The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-immune metabolic tug-of-war: from immune escape to targeting metabolic rewiring in cancer therapy.

Frontiers in cell and developmental biology·2026
Same author

Profiling of extracellular vesicles from primary hepatocytes, organoids, and mash patients identifies cell injury-specific signatures.

Scientific reports·2026
Same author

Endothelial cell glycogen synthase kinase 3β promotes lipotoxic endotheliopathy and liver inflammation in MASH.

JCI insight·2026
Same author

Inhibition of the SerpinB3/protease-activated receptor 2 axis reduces liver cancer development and affects lipid metabolism.

British journal of cancer·2026
Same author

Decoding the tumor microenvironmental program behind HCC recurrence after incomplete radiofrequency ablation.

Hepatology (Baltimore, Md.)·2026
Same author

Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in Hepatoblastoma.

Liver international : official journal of the International Association for the Study of the Liver·2026

Related Experiment Video

Updated: Jun 12, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Liver fibrosis: a dynamic and potentially reversible process.

Davide Povero1, Chiara Busletta, Erica Novo

  • 1Department of Experimental Medicine and Oncology, University of Torino, Italy.

Histology and Histopathology
|June 17, 2010
PubMed
Summary

Chronic liver injury drives fibrosis and cirrhosis through inflammation and wound healing. While liver fibrosis can regress with treatment, established cirrhosis reversal remains challenging in humans.

More Related Videos

Cell Type-specific Gene Expression Profiling in the Mouse Liver
10:06

Cell Type-specific Gene Expression Profiling in the Mouse Liver

Published on: September 17, 2019

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis
06:46

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

Related Experiment Videos

Last Updated: Jun 12, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Cell Type-specific Gene Expression Profiling in the Mouse Liver
10:06

Cell Type-specific Gene Expression Profiling in the Mouse Liver

Published on: September 17, 2019

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis
06:46

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

Area of Science:

  • Hepatology
  • Cell Biology
  • Pathology

Background:

  • Chronic liver diseases (CLDs) cause persistent inflammation and fibrogenesis, leading to liver cirrhosis.
  • Cirrhosis involves fibrous septa, altered vascular architecture, and portal hypertension.
  • Activated hepatic stellate cells (HSC/MFs) are key drivers of liver fibrogenesis.

Purpose of the Study:

  • To review the mechanisms of liver fibrogenesis and explore the potential for fibrosis regression.
  • To discuss the role of myofibroblast-like cells (MFs) and epithelial-mesenchymal transition (EMT) in fibrosis.
  • To evaluate the evidence for reversing liver fibrosis and cirrhosis.

Main Methods:

  • Review of experimental and clinical literature on liver fibrosis and cirrhosis.
  • Analysis of cellular mechanisms including HSC/MF activation and apoptosis.
  • Examination of factors influencing fibrosis progression and regression.

Main Results:

  • Liver fibrogenesis is driven by chronic injury, inflammation, and wound healing responses.
  • Oxidative stress and epithelial-mesenchymal transition (EMT) contribute to fibrosis.
  • While fibrosis regression is possible, complete reversal of established cirrhosis is not unequivocally demonstrated in humans.

Conclusions:

  • Liver fibrosis, though traditionally viewed as irreversible, shows potential for regression upon removal of etiological agents or effective therapy.
  • Human HSC/MFs are more resistant to apoptosis than murine counterparts, complicating fibrosis reversal.
  • Further research is needed to achieve significant reversal of established cirrhosis and its vascular complications.